As of 3:59pm ET
| +0.02 / +1.50%|
The 1 analysts offering 12-month price forecasts for Aviragen Therapeutics Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +270.37% increase from the last price of 1.35.
The current consensus among 1 polled investment analysts is to Buy stock in Aviragen Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.